4.7 Article

A Colon-Targeted Prodrug of Riluzole Improves Therapeutic Effectiveness and Safety upon Drug Repositioning of Riluzole to an Anti-Colitic Drug

期刊

MOLECULAR PHARMACEUTICS
卷 19, 期 11, 页码 3784-3794

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.2c00255

关键词

riluzole; colon-targeted drug delivery; colitis; prodrug; drug repositioning

资金

  1. Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2021R1I1A3A0403710411]

向作者/读者索取更多资源

This study investigates the feasibility of repurposing riluzole (RLZ) as an anti-inflammatory bowel disease (IBD) drug. Oral RLZ effectively inhibits rat colitis, but has safety concerns and limited systemic absorption. By coupling RLZ with salicylic acid to form RAS, oral RAS can be targeted to the colon and inhibit inflammation, and it is more effective than current anti-IBD drugs.
Riluzole (RLZ) is a neuroprotective drug indicated for amyotrophic lateral sclerosis. To examine the feasibility of RLZ for repositioning as an anti-inflammatory bowel disease (IBD) drug, RLZ (2, 5, and 10 mg/kg) was administered orally to rats with colitis induced by 2,4-dinitrobenzenesulfonic acid. Oral RLZ was effective against rat colitis in a dose-dependent manner, which was statistically significant at doses over 5 mg/kg. To address safety issues upon repositioning and further improve anti-colitic effectiveness, RLZ was coupled with salicylic acid (SA) via an azo-bond to yield RLZ-azo-SA (RAS) for the targeted colonic delivery of RLZ. Upon oral gavage, RAS (oral RAS) was efficiently delivered to and activated to RLZ in the large intestine, and systemic absorption of RLZ was substantially reduced. Oral RAS ameliorated colonic damage and inflammation in rat colitis and was more effective than oral RLZ and sulfasalazine, a current anti-IBD drug. Moreover, oral RAS potently inhibited glycogen synthase kinase 3 beta (GSK3 beta) in the inflamed distal colon, leading to the suppression of NF kappa B activity and an increase in the level of the anti-inflammatory cytokine interleukin-10. Taken together, RAS, which enables RLZ to be delivered to and inhibit GSK3 beta in the inflamed colon, may facilitate repositioning of RLZ as an anti-IBD drug.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据